You are here
Articles
Posted on Thursday, May 10, 2012 - 12:56pm
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib
E Weisberg1,5, A K Azab1,5, P W Manley2, A L Kung3, A L Christie3, R Bronson4, I M...
Posted on Thursday, May 3, 2012 - 11:49am
My Approach to Chronic Myeloid Leukemia
Interview by L Scott Zoeller. 2012 Apr 3, Tim Hughes, MD
Posted on Thursday, May 3, 2012 - 11:41am
Stopping Dasatinib and Nilotinib Explored in Chronic Myeloid Leukemia
Elsevier Global Medical News. 2011 Jun 30, S Freeman
Posted on Sunday, April 15, 2012 - 8:08pm
In the circumstances we feel we have done all we can and that an appeal is not a
positive option for us. We feel our focus must now shift to ensuring that applications to the Cancer Drugs Fund are successful on every...
Posted on Thursday, March 29, 2012 - 1:27am
<span id="welcome_story">
<a style="float: right; padding-left: 8px;" href="...
Posted on Friday, March 23, 2012 - 10:24am
In the circumstances we feel we have done all we can and that an appeal is not a positive option for us.
Posted on Wednesday, March 7, 2012 - 12:57pm
Leukemia 26, 490-498 (March 2012) | doi:10.1038/leu.2011.231
Posted on Wednesday, February 22, 2012 - 2:10pm
Clinical Care Options Oncology
Chronic Myeloid Leukaemia Treatment in Evolution: Recent Advances in Therapy. Moshe Talpaz, MD.
Posted on Sunday, February 5, 2012 - 12:41pm
Abstract
The outcome of chronic myeloid leukemia (CML) has been profoundly changed by the introduction of tyrosine kinase inhibitors into therapy, but the prognosis of patients with CML is still...
Posted on Sunday, February 5, 2012 - 11:40am
Elsevier Global Medical News. 2011 Jun 23, S Freeman
Posted on Monday, January 30, 2012 - 4:46pm
Not Only Response but Early Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Jorge Cortes, January 2012
Posted on Wednesday, January 25, 2012 - 2:39pm
Purpose:
We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular...
Posted on Tuesday, January 24, 2012 - 12:33am
Chronic myeloid leukemia is a model of how the molecular understanding of a disease can provide the platform for therapy and diagnostics. Clinicians are now empowered with first- and second-generation tyrosine kinases,...
Posted on Sunday, January 22, 2012 - 2:31pm
Wendy T Parker, Musei Ho, Hamish S Scott, Timothy P Hughes, Susan Branford.
- ‹ previous
- 19 of 33
- next ›